(MedPage Today) — The FDA on Tuesday approved mirdametinib (Gomekli) for adults and kids ages 2 and up with neurofibromatosis type 1 (NF1).
Approval of the MEK inhibitor is specifically for patients who have symptomatic plexiform neurofibromas…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/114182
Author :
Publish date : 2025-02-11 22:31:40
Copyright for syndicated content belongs to the linked Source.
